Related Experiment Video
Updated: Jul 14, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Rituximab as a treatment option for refractory endogenous anterior uveitis
C Tappeiner1, C Heinz, C Specker
1Department of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.
Background:
To report on anti-CD20 antibody therapy in a patient with uveitis refractive to immunosuppression therapy.
Methods:
Case report with ophthalmoscopic, optical coherence tomography and fluorescein-angiographic findings.
Results:
A 49-year-old woman was suffering from bilateral, noninfectious chronic anterior uveitis refractive to corticosteroids and immunosuppressive drugs. Bilateral visual acuity was 20/100 due to cataract and cystoid macular edema (CME). After treatment with rituximab, vision and CME improved, and uveitis was stable until the final visit (follow-up at 12 months).
Conclusion:
The case report suggests that rituximab may be helpful for selected patients with chronic anterior uveitis refractive to corticosteroids and immunosuppressive medication.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment